55289959 Label (55289959)
Gabapentin Tablet
Product Images NDC 55289-959
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 55289-959). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1
Figure2
This appears to be a chart or table displaying mean pain scores for a study with different dosing periods and treatment options, including a placebo, gabapentin at 1800 mg/day, and gabapentin at 2400 mg/day. The chart includes a baseline measurement and a 4-week and 8-week fixed dose period.*
Figure3
The given description comprises the result table of two controlled clinical studies on PHN (Postherpetic Neuralgia) treatments, along with the proportion of responders, which are patients that achieved a 50% reduction in pain score at Endpoint. The table shows various percentages for PHN treatments, and the asterisk symbols indicate the level of significance.*
Figure4
Structure.jpg (Structure)
Equation.jpg (Equation)
This is a calculation for estimating the glomerular filtration rate (GFR) based on age, weight, and serum creatinine levels of a patient. The first formula uses age in years and weight in kilograms, while the second formula uses serum creatinine levels in milligrams per deciliter. The second formula also includes an adjustment factor of 0.85 for female patients. This information may be used in assessing the renal function of a patient.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
